EASD 2026 Rome September 28 Through October 2 Sets Up September Obesity Peptide Catalyst Calendar Anchored on Amylin Data
The European Association for the Study of Diabetes (EASD) 62nd Annual Meeting takes place in Rome September 28 through October 2, 2026, and sets up the largest single September catalyst window for obesity-peptide investor and clinical interest. AstraZeneca will present Phase 2 data on AZD6234 (selective amylin receptor peptide agonist) monotherapy from APRICUS plus the ASCEND Phase 2b combination with AZD9550 GLP-1/glucagon dual agonist. Zealand Pharma and Roche will present petrelintide (amylin analog) data from ZUPREME-2 (obesity plus type 2 diabetes) with the Phase 3 monotherapy program preparing to initiate late 2026. Novo Nordisk will present amycretin (long-acting GLP-1/amylin dual agonist) plus CagriSema follow-through data. The EASD calendar coincides with the Roche Pharma Day investor event on Monday September 28, 2026 that will update on the top-three-obesity-portfolio (petrelintide, enicepatide, HM17321). Ascendis Pharma is also expected to provide TransCon CNP achondroplasia updates.